CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM

RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were met and there was no survival benefit from adding d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew, Stern, Yaakov, Wang, Tony, Aldape, Kenneth, Armstrong, Terri, Vogelbaum, Michael, Sulman, Erik, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Gan, Hui, Preusser, Matthias, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, de Vos, Filip, Hsu, Sigmund, Cardona, Andres, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frenay, Christine, Wick, Antje, Pugh, Stephanie, Curran, Walter, Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.217
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados